The FDA is considering a first approval of a deuterated drug, and large pharmaceutical companies have started to incorporate 'heavy hydrogen' into novel candidates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transition-metal-free silylboronate-mediated cross-couplings of organic fluorides with amines
Nature Communications Open Access 03 April 2023
-
A general synthesis of azetidines by copper-catalysed photoinduced anti-Baldwin radical cyclization of ynamides
Nature Communications Open Access 28 January 2022
-
Organophotocatalytic selective deuterodehalogenation of aryl or alkyl chlorides
Nature Communications Open Access 17 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov 15, 219–221 (2016). https://doi.org/10.1038/nrd.2016.63
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.63
This article is cited by
-
Transition-metal-free silylboronate-mediated cross-couplings of organic fluorides with amines
Nature Communications (2023)
-
A general synthesis of azetidines by copper-catalysed photoinduced anti-Baldwin radical cyclization of ynamides
Nature Communications (2022)
-
[18F]Difluorocarbene for positron emission tomography
Nature (2022)
-
Organophotocatalytic selective deuterodehalogenation of aryl or alkyl chlorides
Nature Communications (2021)
-
Semiconductor photocatalysis to engineering deuterated N-alkyl pharmaceuticals enabled by synergistic activation of water and alkanols
Nature Communications (2020)
